IPN60300
Sponsors
Ipsen Pharma, Ipsen
Conditions
Advanced or metastatic solid tumoursLocally Advanced Solid TumorMetastatic Solid Tumor
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RecruitingNCT07213817
Start: 2025-12-05End: 2028-10-30Target: 114Updated: 2026-09-01
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.
Not yet recruitingCTIS2025-522139-33-00
Target: 28Updated: 2025-12-23